Mesothelin-targeted CAR-T cell therapy for solid tumors.
View/ Open
Date
2021-04-03ICR Author
Author
Klampatsa, A
Dimou, V
Albelda, SM
Type
Journal Article
Metadata
Show full item recordAbstract
Introduction: Mesothelin (MSLN) is a tumor differentiation antigen normally restricted to the body's mesothelial surfaces, but significantly overexpressed in a broad range of solid tumors. For this reason, MSLN has emerged as an important target for the development of novel immunotherapies. This review focuses on anti-MSLN chimeric antigen receptor (CAR) T cell immunotherapy approaches.Areas covered: A brief overview of MSLN as a therapeutic target and existing anti-MSLN antibody-based drugs and vaccines is provided. A detailed account of anti-MSLN CAR-T cell approaches utilized in preclinical models is presented. Finally, a comprehensive summary of currently ongoing and completed anti-MSLN CAR-T cell clinical trials is discussed.Expert opinion: Initial trials using anti-MSLN CAR-T cells have been safe, but efficacy has been limited. Employing regional routes of delivery, introducing novel modifications leading to enhanced tumor infiltration and persistence, and improved safety profiles and combining anti-MSLN CAR-T cells with standard therapies, could render them more efficacious in the treatment of solid malignancies.
Collections
Research team
Thoracic Oncology Immunotherapy Group (TOIG)
Thoracic Oncology Immunotherapy Group (TOIG)
Language
eng
Date accepted
2020-10-26
License start date
2020-11-12
Citation
Expert opinion on biological therapy, 2020, pp. 1 - 14
Publisher
TAYLOR & FRANCIS LTD